Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2020-11-05 Interim / Quarterly Rep…
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS' for the period ended September 30, 2020, and includes detailed financial statements such as balance sheets, statements of loss and comprehensive loss, changes in shareholders' equity, and cash flows. It also contains notes to the financial statements and discusses accounting policies and business descriptions. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of unaudited interim financial statements prepared under IFRS and the reference to IAS 34 (Interim Financial Reporting) confirms this is an interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-11-05 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report for Profound Medical Corp. covering the third quarter ended September 30, 2020. It includes comprehensive financial statements such as balance sheets, statements of loss and comprehensive loss, and cash flows, all unaudited but prepared according to IFRS and IAS 34 for interim financial reporting. The text also contains management commentary on financial results, operational highlights, liquidity, share capital, and a conference call announcement. The presence of actual financial data and analysis for a quarterly period, along with the explicit mention of the third quarter 2020, indicates this is an Interim / Quarterly Report. It is not merely an earnings release or a brief summary but a substantive financial report for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2020
2020-11-05 English
News release - English.pdf
Regulatory Filings
2020-10-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Profound Medical will present at the Cantor Virtual Global Healthcare Conference. It describes the upcoming presentation event, the company's business, and forward-looking statements. There is no financial data, no detailed report, no voting results, no management changes, no earnings release, or any other specific regulatory filing content. The document is an announcement of a presentation event rather than the presentation itself or a financial report. Given the content and length (4688 characters), it fits best as an Investor Presentation announcement or a general Regulatory Filing. However, since it is announcing a presentation event rather than providing the presentation itself, and it is a press release, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2020-09-09 English
News release - English.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing that Profound Medical Corp. will present an update at the Canaccord Genuity 40th Annual Growth Conference. It describes the upcoming presentation event, the company's business, and forward-looking statements. There are no financial statements, detailed financial data, or regulatory filings included. The document is an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP). The document length is under 5,000 characters, but it is not merely announcing a report publication; it is announcing a presentation event.
2020-08-10 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three and six months ended June 30, 2020. It references unaudited interim condensed consolidated financial statements prepared under IFRS and IAS 34, which governs interim financial reporting. The content includes detailed discussion of business overview, forward-looking statements, COVID-19 impact, product descriptions, and clinical data. The length is substantial (15,000 characters), and the document contains substantive financial and operational analysis rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial reports for periods shorter than a full fiscal year with actual financial data and analysis. H1 2020
2020-08-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.